A patient was presented with four days of vomiting, abdominal pain and sweating. At presentation the Capillary Blood Glucose (CBG) was 1.7 mmol/L, the Blood Pressure (BP) was 182/102 mmHg, and the pulse 100 bpm. on examination, he was sweaty, pale and cold. The initial differential diagnosis was hypoglycaemia secondary to insulin abuse, hypoadrenalism or insulinoma, the transient hypertension being considered a consequence of sympathetic stimulation. He remained clinically well overnight with a CBG of 10-14 mmol/L following intravenous glucose. The next morning he complained of nausea and abdominal pain. The BP had risen to 203/127 mmHg when he was later reviewed, having been given 10mg intramuscular metoclopramide. Shortly afterwards, he developed acute pulmonary oedema and had become hypoglycaemic again; a phaeochromocytoma crisis was suspected. Treatment with α-adrenoceptor blockade with intravenous phenoxybenzamine was advised. However, the patient deteriorated and died in the Intensive Care Unit within two hours. Autopsy examination confirmed a phaeochromocytoma in the left adrenal, with haemorrhage within the head of pancreas, but no evidence of a pancreatic tumour.
This is an unusual case of a phaeochromocytoma crisis presenting primarily with hypoglycaemia. The tumour did not stain for insulin and the mechanism of the hypoglycaemia remains unclear, but we suspect that this may have occurred via -adrenoceptor-mediated release of insulin from the pancreas.
case descrIptIon

History
A 47-year old man from Eastern Europe was referred to the acute medical team complaining of a 4-day history of vomiting, abdominal pain and profuse sweating. He had been noted by the referring doctor to be hypoglycaemic, with a Capillary Blood Glucose (CBG) of 1.5 and 1.8 mmol/L on two separate occa-followed by an intravenous infusion of 5% glucose; 100mg hydrocortisone was given intramuscularly whilst awaiting serum cortisol levels. The results of the initial investigations are given below. The patient initially made a good response and appeared well, his sweating resolved and blood pressure remained around 115/60 mmHg overnight with a CBG of 14.2 mmol/L. However, the following morning the patient again became sweaty and nauseated, with a blood pressure of 202/127 mmHg and he complained of colicky abdominal pain; 10mg intramuscular metoclopramide was administered. Further blood pressure measurements revealed that he was persistently extremely hypertensive, and the CBG had now fallen to 1.7 mmol/L. The possibility of a phaeochromocytoma was raised, although the hypoglycaemia remained puzzling. Over the next four hours he deteriorated and developed frank pulmonary oedema; 80mg intravenous furosemide was given and an intravenous glyceryl trinitrate infusion commenced. The patient was moved to the Intensive Care Unit with a presumed phaeochromocytoma crisis. On arrival he had become profoundly hypotensive and underwent a cardiac arrest before intravenous -adrenoreceptor blockade with phenoxybenzamine could be commenced. Attempts to resuscitate him were unsuccessful. A hospital autopsy examination was carried out three days later. (Table 1) Prior to the instigation of any treatment, plasma glucose was confirmed at 1.8 mmol/L, with inappropriately raised insulin and C-peptide levels of 25.9 mIU/L and 1174 pmol/L, respectively (reference range in the presence of hypoglycaemia are <3 mIU/ml and 200 pmol/L, respectively). At presentation, the alcohol level was less than 10 mg/dL and lactate 1.7 mmol/L (reference range, 0.5-2.2). Serum cortisol was 1202 nmol/L, excluding adrenal insufficiency, with normal levels of thyroid function tests, prolactin and IGF-1 (99ng/mL; normal median 154).
Results of investigations
Following his dramatic clinical deterioration, the serum creatinine rose from 103μmol/L at presentation to 262 μmol/L, blood urea rose from 8.3 to 13.6 mmol/L, amylase from 244 mmol/L to 722 mmol/L, ALT 16 to 830U/L, while creatine kinase rose from 117U/L to 722U/L. Troponin T had risen to 3.4 mcg/L. Toxicological analysis for amphetamines was negative but revealed the presence of tetrahydrocannabinoids, sions. His blood pressure was 182/112 mmHg.
On the day of admission he had become increasingly tremulous and sweaty. He worked as a personal trainer in a local gym and had been very well until the time of presentation. He had no headache or visual symptoms and had experienced no recent change in weight; there was no known history of hypertension or diabetes mellitus and he was taking no prescribed medication. He had no obvious symptoms of neuroglycopaenia.
He vehemently denied abusing insulin, amphetamines or growth hormone, although he did admit to having abused anabolic steroids 15 years previously and to smoking marijuana occasionally. A friend later informed us that he also took tablets known as "fat burners", which were purchased legally and believed to contain large amounts of caffeine.
His father and a sister were well and living in the Former Yugoslav Republic of Macedonia. There was no family history of note. He smoked 10 cigarettes per day and had previously smoked more heavily but denied any alcohol consumption. There was nothing to note on systemic enquiry.
Examination
He looked extremely unwell on presentation: he was pale and sweating profusely, peripherally cyanosed and shivering. He was muscular with a Body Mass Index (BMI) of 27.5. He had no increased skin or buccal mucosa pigmentation. His pulse was 100 beats per minute and regular with a blood pressure of 182/102 mmHg on initial presentation falling to 115/90 mmHg after 30 minutes, both levels being recumbent as he was too ill to be examined standing. There were no signs of heart failure; examination of the respiratory system and abdomen was normal apart from an appendicectomy scar. His visual fields were normal to confrontation; tone, power, coordination and reflexes were all normal and symmetrical. His glucose level was 1.8 mmol/L, fasting, with a BP of 115/90 mmHg.
At this stage the differential was between exogenous insulin abuse, an insulin-secreting endocrine tumour or hypoadrenalism.
Management and Clinical Course
50mls 50% glucose was administered intravenously An echocardiogram in the Intensive Care Unit showed the left ventricular systolic function was severely reduced with an ejection fraction of 15%-20% and plain chest radiology confirmed pulmonary oedema. (Figures 1-3) A post-mortem examination confirmed the presence of a phaeochromocytoma in the left adrenal: the tumour measured 6.5x6.5 cm with central haemorrhage. The phaeochromocytoma stained with chromogranin and synaptophysin, with positivity of S100 for sustentacular cells. However, the tumour was immunohistochemically negative for insulin. The head of pancreas also showed haemorrhage, but there was no evidence of a pancreatic tumour throughout the pancreas. Histological examination of the heart revealed patchy oedematous changes.
Post-mortem examination
dIscussIon
This is an unusual case of a phaeochromocytoma crisis presenting with hypoglycaemia and only later with hypertension. The tumour did not stain for insulin and the mechanism of the hypoglycaemia remains unclear. There was no islet cell tumour anywhere in the pancreas, the high levels of C-peptide suggest that there was no exogenous insulin administered, and testing for insulin secretagogues was negative. This implies that the high and inappropriate levels of insulin were a direct eutopic islet cell response to the phaeochromoctyoma.
Phaeochromocytoma is classically associated with hyperglycaemia. Excess catecholamine secretion by such tumours inhibit the release of insulin from the pancreas by α-adrenoceptor stimulation.
1,2 However, in contrast, stimulation of the β-adrenoceptors results in increased release of insulin from the pancreatic cells. 1 One hypothesis is that in this patient the profound hypoglycaemia witnessed resulted from a dominant β-adrenoceptor mediated release of insulin from the pancreas, overriding the α-adrenoceptor mediated 
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on histopathological features. In such cases, tumoural hypoglycaemia can be secondary to the ectopic secretion of factors related to IGF-II; this is extremely unlikely in this instance as one would then expect C-peptide levels to be suppressed.
We believe that his case demonstrates the importance of recognising that a phaeochromocytoma crisis can be associated with hypoglycaemia as well as the more frequently described hyperglycaemia, and possible mechanisms for this phenomenon have been discussed. Our patient showed only intermittent hypertension, which could be attributed to previous caffeine and marijuana use, or to sympatho-adrenal activations caused by hypoglycaemia. Previous data have shown correlations between the size of a tumour, the rate of turnover of catecholamines within the tumour and the pattern of catecholamine metabolites in the urine. 10 It has been suggested that in some phaeochromocytomas much of the catecholamine synthesised is degraded directly in the tumour before it ever reaches the circulation. This process may partially "protect" the patient from the cardiovascular effects of his tumour and thereby modify the clinical course of the disease. 10 Indeed, this theory may account for the later presentation of the cardiovascular effects seen in our patient and the normal levels of urinary catecholamines found.
The case also serves to remind clinicians that metoclopramide can cause the release of catecholamines in patients with phaeochromocytomas, although the preceding acute administration of hydrocortisone may also be a salient factor. 11 Leow and Loh reported three patients with phaeochromocytomas who developed acute crises after being given metoclopramide. 12 Stimulation of the dopamine type 2 receptors on presynaptic nerve endings inhibits the release of catecholamines and ganglion transmission, while metoclopramide accentuates noradrenaline release via presynaptic type 2-dopamine receptor blockade; it may also have a direct effect on catecholamines release from phaeochromocytomas. 13, 14 It may thus act as a potent trigger of a hypertensive crisis in the presence of a phaeochromocytoma. In summary, in the light of this case, phaeochromocytoma may be considered a rare but important cause of hypoglycaemia. inhibition of insulin release and hence inappropriately high insulin levels for the prevailing plasma glucose levels. 3, 4 The patient took regular strenuous exercise and had also been vomiting for the four days prior to presentation: his hepatic and skeletal muscle glycogen stores were thus likely to have been depleted, which may have exacerbated the insulin effect. In general, the regulation of insulin is under dominant inhibitory -adrenoceptor control, principally via the 2-adrenoceptor, with an increase in glucose tolerance on treatment of the phaeochromocytoma. 5 However, as noted above, glycogen stores may have been depleted, and it is conceivable that if adrenaline rather than noradrenaline release was favoured, then -adrenoceptor-mediated effects may have become dominant, even though -adrenoceptors can be shown to increase insulin resistance in vitro. 6 Another possible mechanism for the inappropriately high insulin levels in this patient include direct release from damaged pancreatic tissue given the large area of haemorrhage found at the time of post-mortem examination. There also are several case reports of severe hypoglycaemia occurring postoperatively in patients undergoing adrenalectomy for phaeochromocytoma, and it is possible that infarction of such a tumour may have the same effect. 7 However, there was only a small area of central haemorrhage in this tumour post-mortem, making this an unlikely contributory factor.
There have been very few case reports of patients with a phaeochromocytoma presenting with hypoglycaemia. Uysel and colleagues described the case of a patient presenting with an insulin-secreting paraganglioma, while Innerman and colleagues reported a patient presenting with hypoglycaemia and a phaeochromocytoma metastatic to the liver. 8, 9 The mechanism of hypoglycaemia is clear in the former case, while in the latter several explanations proposed by the authors included secretion of insulin or a substance with insulin-like activity by the tumour, decreased gluconeogenesis, disruption of glucagon metabolism, increased utilisation of glucose by the tumour and/or a local effect of the tumour on the hepatic parenchyma. Finally, the phaeochromocytoma in our patient was large, increasing the chance of malignancy, a diagnosis which can rarely be made
